Ultragenyx posts preliminary 2025 revenue update

Ultragenyx Pharmaceutical Inc. filed a current report to note that it has issued a press release with preliminary unaudited fiscal year 2025 results.

Accepted by SEC EDGAR 01/12/2026 - 07:45 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. filed a current report to note that it has issued a press release with preliminary unaudited fiscal year 2025 results. The release covers total revenue for the year, as well as revenue contributions from its key products Crysvita® and Dojolvi®, plus the company’s cash and investment balances at the end of the 2025 fiscal year. Ultragenyx plans to report full audited results for the 2025 fiscal year in February 2026. The company specifies that this preliminary financial information and the accompanying press release are being furnished rather than filed under securities laws.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ultragenyx (RARE) disclose in this 8-K filing?

Ultragenyx disclosed that it issued a press release with preliminary unaudited fiscal year 2025 total revenue, revenue for Crysvita® and Dojolvi®, and its cash and investments at 2025 year-end.

Does this Ultragenyx (RARE) 8-K include full 2025 financial results?

No, the company states it has only provided preliminary unaudited fiscal year 2025 figures in a press release and expects to report its full year results in February 2026.

Where can investors find the preliminary 2025 numbers for Ultragenyx (RARE)?

The specific preliminary figures are contained in Exhibit 99.1, which is the press release dated January 12, 2026 that Ultragenyx furnished with this report.

How does the 8-K describe the status of Ultragenyx’s preliminary 2025 data?

The company describes the 2025 financial information as preliminary and unaudited, indicating it is an early view ahead of the full year report.

Are the Ultragenyx (RARE) preliminary 2025 results considered filed with the SEC?

Ultragenyx states that the information under Item 2.02 and in Exhibit 99.1 is being furnished, not filed, and is not incorporated into other securities filings unless specifically referenced.

Which Ultragenyx products are highlighted in the preliminary 2025 revenue disclosure?

The preliminary release highlights revenue for Crysvita® and Dojolvi® in addition to Ultragenyx’s total revenue and year-end cash and investments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001515673false00015156732026-01-122026-01-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

Ultragenyx Pharmaceutical Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-36276	27-2546083
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
60 Leveroni Court
Novato, California				94949
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 415 483-8800

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		RARE		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 12, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release (the “Press Release”) announcing preliminary unaudited fiscal year 2025 total revenue results, revenue for Crysvita® and revenue for Dojolvi®and cash and investments at 2025 fiscal year end. The Company expects to report its full year results for the 2025 fiscal year in February 2026. A copy of the Press Release is furnished herewith as Exhibit 99.1.

The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release, dated January 12, 2026
104	The cover page from the Company’s Current Report on Form 8-K dated January 12, 2026 formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Ultragenyx Pharmaceutical
Date:	January 12, 2026	By:	/s/ Howard Horn
			Howard Horn Executive Vice President, Chief Financial Officer, Corporate Strategy